FDA Regulatory Strategy & Pre-Sub Planning
Regulatory pathway selection, predicate logic, and pre-submission alignment determine FDA review success
Key Outcomes
Regulatory strategy supported by classification and predicate reasoning
A clear predicate device analysis or approval rationale
Q-Sub materials aligned with FDA review expectations
Greater predictability and reduced regulatory risk
Medical device companies entering the US market require a structured FDA regulatory strategy that aligns device classification, predicate logic, intended use, labeling, and evidence expectations. Early regulatory decisions influence whether a device follows a 510(k), De Novo, or PMA pathway, and these decisions define testing requirements, clinical evidence, human factors planning, and downstream commercial sequencing. Many MedTech companies experience delays because their pre-submission planning, device description, and benefit-risk narrative do not reflect FDA review expectations.
UnifiMed provides a unified regulatory strategy that connects scientific rationale, clinical feasibility, risk controls, and commercial intent to support predictable and efficient FDA interactions.
CHALLENGES
Early Regulatory Mistakes Create Downstream FDA Risk
Across early-stage and international MedTech companies, several issues consistently delay regulatory progress
Inadequate predicate device analysis or misaligned substantial equivalence rationale
Intended use and claims that exceed device functionality or available clinical evidence
Incomplete testing requirements across bench, biocompatibility, software, and usability
Misalignment between labeling, risk profile, and US regulatory pathway requirements
Evidence plans that do not meet FDA review expectations for safety and performance
Q-Sub packages that do not fully address FDA’s core regulatory questions, evidence expectations, or pathway justification
These gaps result in deficiencies, extended review cycles, and regulatory uncertainty that slows US market entry
OUR PROCESS
How We Build FDA Regulatory Strategy and Pre-Sub Planning
UnifiMed provides an integrated strategy that strengthens early interactions with FDA and supports a predictable regulatory pathway
Regulatory Pathway Determination
We define whether the device aligns with a 510(k), De Novo, or PMA pathway based on design, intended use, technological characteristics, and risk profile. This establishes the correct regulatory foundation before any evidence or submission planning begins
Predicate Device Assessment
We evaluate predicate or reference devices, map intended use alignment, compare technological characteristics, and determine feasibility of substantial equivalence. This informs pathway selection and clarifies downstream evidence requirements
Pre-Sub Strategy & Q-Sub Preparation
We develop a structured pre-submission plan that supports productive FDA interaction. This includes Q-Sub content, targeted regulatory questions, briefing packages, and meeting preparation to ensure clarity on testing, evidence, and pathway expectations
Labeling, Claims, and Intended Use
We refine intended use, indications, and claims to ensure they match device functionality, evidence, and FDA review expectations. This prevents misalignment that can trigger deficiencies, additional testing, or pathway reclassification
Testing & Evidence Requirements
We define the testing and evidence plan needed for regulatory success, including bench, biocompatibility, electrical safety, software, cybersecurity, human factors, and clinical evidence. This ensures all elements support the selected pathway
Risk Management Integration
We align risk controls with ISO 14971 and FDA expectations, ensuring risk documentation supports claims, testing plans, labeling decisions, and the overall regulatory narrative. This strengthens benefit-risk justification for submission
Ready to Learn More?
Contact our team to discuss how we can support your FDA regulatory strategy and pre-submission planning